Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Ferrannini

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
International Journal of Cardiology|November 20, 2021
Mannose as a biomarker of coronary artery disease: Angiographic evidence and clinical significanceEle Ferrannini, Nikolaus Marx, Daniele Andreini, et al.
European Journal of Heart Failure|August 1, 2024
Characterizing atrial fibrillation in patients with and without heart failure across the ejection fraction spectrum: Incidence, prevalence, and treatment strategiesValeria Valente, Giulia Ferrannini, Lina Benson, et al.
Diabetes Care|January 29, 2020
Coronary Artery Disease and Type 2 Diabetes: A Proteomic StudyGiulia Ferrannini, Maria Laura Manca, Marco Magnoni, et al.
European Journal of Preventive Cardiology|August 14, 2025
Pharmacological treatment patterns and outcomes according to the coexistence of heart failure and type 2 diabetes: data from the Swedish Heart Failure Registry and National Diabetes RegistryFrancesca Musella, Giulia Ferrannini, Lina Benson, et al.
European Journal of Heart Failure|June 16, 2023
Eligibility for vericiguat in a real-world heart failure population according to trial, guideline and label criteria: Data from the Swedish Heart Failure RegistryNgoc V Nguyen, Felix Lindberg, Lina Benson, et al.
Journal of Clinical Periodontology|September 12, 2024
Does Periodontitis Increase the Risk for Future Cardiovascular Events? Long-Term Follow-Up of the PAROKRANK StudyAnna Norhammar, Per Näsman, Kåre Buhlin, et al.
European Journal of Heart Failure|February 18, 2021
Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure RegistryPeter M Becher, Benedikt Schrage, Giulia Ferrannini, et al.
JACC. Heart Failure|October 4, 2025
Iron Deficiency Definitions in Heart Failure Across Ejection Fraction Phenotypes: Prevalence, Symptoms, and Cause-Specific OutcomesFelix Lindberg, Carin Corovic Cabrera, Lina Benson, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|April 17, 2024
Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes RegistriesMarkus Wallner, Mattia Emanuele Biber, Davide Stolfo, et al.
European Heart Journal|November 16, 2020
Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metforminGiulia Ferrannini, Hertzel Gerstein, Helen Martina Colhoun, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
International Journal of Cardiology|November 20, 2021
Mannose as a biomarker of coronary artery disease: Angiographic evidence and clinical significanceEle Ferrannini, Nikolaus Marx, Daniele Andreini, et al.
European Journal of Heart Failure|August 1, 2024
Characterizing atrial fibrillation in patients with and without heart failure across the ejection fraction spectrum: Incidence, prevalence, and treatment strategiesValeria Valente, Giulia Ferrannini, Lina Benson, et al.
Diabetes Care|January 29, 2020
Coronary Artery Disease and Type 2 Diabetes: A Proteomic StudyGiulia Ferrannini, Maria Laura Manca, Marco Magnoni, et al.
European Journal of Preventive Cardiology|August 14, 2025
Pharmacological treatment patterns and outcomes according to the coexistence of heart failure and type 2 diabetes: data from the Swedish Heart Failure Registry and National Diabetes RegistryFrancesca Musella, Giulia Ferrannini, Lina Benson, et al.
European Journal of Heart Failure|June 16, 2023
Eligibility for vericiguat in a real-world heart failure population according to trial, guideline and label criteria: Data from the Swedish Heart Failure RegistryNgoc V Nguyen, Felix Lindberg, Lina Benson, et al.
Journal of Clinical Periodontology|September 12, 2024
Does Periodontitis Increase the Risk for Future Cardiovascular Events? Long-Term Follow-Up of the PAROKRANK StudyAnna Norhammar, Per Näsman, Kåre Buhlin, et al.
European Journal of Heart Failure|February 18, 2021
Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure RegistryPeter M Becher, Benedikt Schrage, Giulia Ferrannini, et al.
JACC. Heart Failure|October 4, 2025
Iron Deficiency Definitions in Heart Failure Across Ejection Fraction Phenotypes: Prevalence, Symptoms, and Cause-Specific OutcomesFelix Lindberg, Carin Corovic Cabrera, Lina Benson, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|April 17, 2024
Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes RegistriesMarkus Wallner, Mattia Emanuele Biber, Davide Stolfo, et al.
European Heart Journal|November 16, 2020
Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metforminGiulia Ferrannini, Hertzel Gerstein, Helen Martina Colhoun, et al.
Pageof 5